October 11, 2021 -- French biotechnology firm GenSight Biologics is highlighting its lenadogene neparvovec (Lumevoq) and GS030 gene therapies at the Cell & Gene Meeting on the Mesa in Carlsbad, CA.
Dr. Magali Taiel, the company's chief medical officer, will present virtually during a prerecorded session on developments in the pipeline for the two therapies. Lumevoq is designed to treat vision loss caused by Leber hereditary optic neuropathy, while GS030 is for retinitis pigmentosa.
Already have an account? Sign in Here
To access all ScienceBoard content create a free account now: